The Neuro-CERVO Alliance for Drug Discovery (NCADD), a new partnership between The Neuro (Montreal Neurological Institute-Hospital) at McGill University and the CERVO Brain Research Centre of the CIUSSS de la Capitale-Nationale, affilitated with l’Université Laval, was awarded $7M CAD in funding over three years from the Ministry of Economy and Innovation
The Canada Foundation for Innovation supports innovative projects that tackle global challenges
Exciting initiatives involving researchers at The Neuro are among the latest getting support under The Canada Foundation for Innovation’s Innovation Fund competition.
April is Parkinson’s Awareness Month, a time to give special attention to a disease that affects approximately 100,000 Canadians. As a centre for both research and clinical treatment of Parkinson’s disease (PD), the Montreal Neurological Institute and Hospital (The Neuro) offers many specialized services and opportunities to participate in research to PD patients.
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
ALS takes away the patient’s motor functions one at a time, and the progress of finding effective drugs to counter its insidious effects has been slow. June is ALS Month, a good time to update the public on the latest developments in ALS research taking place at The Neuro.
The Montreal Neurological Institute and Hospital (The Neuro) is recognized as a leading Canadian centre for research into amyotrophic lateral sclerosis (ALS) as well as for its care of ALS patients.
The Montreal Neurological Institute and Hospital (The Neuro) is recognized worldwide for its research and clinical expertise in Parkinson’s disease (PD). PD is a motor neuron disease that is generally associated with old age, but people can also develop it in their thirties and forties.
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
Two researchers at the Montreal Neurological Institute and Hospital (MNI) of McGill University have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.
For many years, the Montreal Neurological Institute and Hospital (The Neuro) and the Research Institute of the McGill University Health Centre have conducted studies that have led to a greater understanding of the nature of Parkinson’s disease (PD). About 100,000 Canadians have PD, a motor neuron disease generally associated with old age, but which can also appear in a person’s thirties or forties.
The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, is at the forefront of Parkinson’s research and clinical care. Parkinson’s patients are seen at The Neuro’s Movement Disorders Clinic and the Montreal General Hospital. Approximately 100,000 Canadians have Parkinson’s disease.
The Neuro to introduce experimental drug treatment
$1 M gift from Mr. J. Sebastian van Berkom launches translational research into neurological disease